Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04459039
Other study ID # 2-106-05-063
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 1, 2018
Est. completion date February 1, 2020

Study information

Verified date July 2020
Source Tri-Service General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

BACKGROUND: Conventional hemorrhoidectomy leads to a high urinary retention rate and fluid restriction is commonly recommended to minimize complications. However, the need for postoperative fluid restriction among patients who have undergone stapled hemorrhoidopexy is unclear. We aimed to determine whether fluid restriction after stapled hemorrhoidopexy with/without partial external hemorrhoidectomy could reduce urinary retention and postoperative pain.

PATIENTS AND METHODS: In this prospective, double-blinded, randomized controlled trial, we enrolled patients who had grade III or IV hemorrhoids and underwent stapled hemorrhoidopexy with/without partial external hemorrhoidectomy; 250 mL/12 h of sterile 0.9% saline was administered to the fluid restriction group after the operation, and 1000 mL/12 h was given to the non-fluid-restriction group. We focused on the need for fluid restriction after stapled hemorrhoidopexy.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date February 1, 2020
Est. primary completion date December 1, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

- Gr. III-IV hemorrhoids paitents

Exclusion Criteria:

- Age<20 or >80

- Allergy to NSAID or opoids

- Impaired renal function

- Pregnant or breast feeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
1000 mL 0.9% sterile saline
Within 12 h of surgery, the experimental group received 1000 mL 0.9% sterile saline intravenously.
250 mL 0.9% sterile saline
Within 12 h of surgery, the control group received 250 mL 0.9% sterile saline intravenously.

Locations

Country Name City State
Taiwan Tri-Service General Hospital, National Defense Medical Center Taipei

Sponsors (1)

Lead Sponsor Collaborator
Tri-Service General Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary first urination the time to first urination after surgery 1 day
See also
  Status Clinical Trial Phase
Completed NCT04016311 - A Brief Mindful Drinking/Eating Intervention for Hemodialysis Patients With Fluid Restrictions N/A